Change of landscape in CLL treatment

At the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation, held in Valencia, Spain, John Gribben, MD, from Barts Cancer Institute, London, UK, discusses the role of ibrutinib, idelalisib, and rituximab in the treatment of patients with chronic lymphocytic leukemia (CLL). The RESONATE-2 clinical trial of ibrutinib changed the treatment algorithm with patients being offered targeted therapies as initial therapy. This raises a question: are we entering a new era where chemotherapy is something in the past for CLL?

Share this video